NSETrading Window26 Jun 2026 · 26 Jun 2026, 12:20 pm

Trading Window

GlaxoSmithKline Pharmaceuticals Limited · GLAXO

✦ AI SummaryRegulatory

GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.

Analysis Scores

Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk8/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

Attachments (1)

📄

GLAXO1924_26062026121939_Tradingwindowclosure.pdf

pdf

Download →
View document text
GlaxoSmithKline Pharmaceuticals Limited GSK House, Dr. Annie Besant Road, Worli, Mumbai - 400 030 Tel No: +91 22 2495 9595 Fax No: +91 22 2495 9494 Web: www.gsk-india.com Email: askus@gsk.com 26th June 2026 BSE LIMITED THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED Phiroze Jeejeebhoy Towers Exchange Plaza, 5th Floor, Plot No. C/1, G Block Dalal Street Bandra-Kurla Complex, Bandra (East) Mumbai - 400001 Mumbai - 400051 Dear Sir, Sub: Closure of “Trading Window” We wish to inform you that in terms of the provisions of SEBI (Prohibition of Insider Trading) Regulations 2015, the trading period for buying or selling of Company's shares is closed from Wednesday, 1st July 2026 till 48 hours after the announcement/declaration of the Un-audited Financial Results of the Company for the first quarter ended 30th June 2026. The date of Board Meeting for declaration of the Un-Audited Financial Results of the Company for the first quarter ended 30th June 2026 will be intimated in due course. Kindly take same on record. Thanking you, Yours faithfully For GlaxoSmithKline Pharmaceuticals Limited Ajay Nadkarni Vice President – Administration, Real Estate & Company Secretary CIN No. L24239MH1924PLC001151